2020 GeneSystems Inc-医療機器分野:企業M&A・提携分析

◆英語タイトル:2020 GeneSystems Inc - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011308
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
20/20 GeneSystems Inc (20/20 Gene) is a medical diagnostic company that develops and commercializes diagnostic tests and proteomics products for early disease detection, therapy selection and biodefense applications. The company provides tests in the areas such as personalized medicine, early detection of lung cancer, and biological detection. 20/20 Gene’s blood test technology is used in the early detection of lung cancer and provides method for analysis of cell signaling in tissue and technologies to detect biological toxins. It offers its products and services to drug companies, biodefense specialists and life scientists for protein analysis. 20/20 Gene is headquartered in Rockville, Maryland, the US.

2020 GeneSystems Inc – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
20/20 GeneSystems Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
20/20 GeneSystems Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
20/20 GeneSystems Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
20/20 GeneSystems Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
20/20 GeneSystems Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
20/20 GeneSystems Inc, Medical Equipment, Deal Details 10
Venture Financing 10
20/20 GeneSystems Raises USD2 Million in Financing Round 10
20/20 GeneSystems Raises USD4.5 Million in Series A Financing 11
20/20 GeneSystems Raises USD2 Million in Financing 12
20/20 Gene Systems Raises USD1 Million in Financing Round 13
20/20 GeneSystems To Raise US$5 Million In Venture Financing 14
20/20 GeneSystems Secures USD0.15 Million in Venture Funding from Maryland Venture Fund 15
Acquisition 16
BHC Center of Financial & Investment Acquires Stake in 20/20 GeneSystems 16
20/20 GeneSystems Inc – Key Competitors 17
20/20 GeneSystems Inc – Key Employees 18
20/20 GeneSystems Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Product News 20
Aug 21, 2017: 20/20’s Lung Cancer Detection Technology Launches in China 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
20/20 GeneSystems Inc, Medical Equipment, Key Facts 2
20/20 GeneSystems Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
20/20 GeneSystems Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
20/20 GeneSystems Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
20/20 GeneSystems Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
20/20 GeneSystems Inc, Deals By Market, 2011 to YTD 2017 8
20/20 GeneSystems Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
20/20 GeneSystems Raises USD2 Million in Financing Round 10
20/20 GeneSystems Raises USD4.5 Million in Series A Financing 11
20/20 GeneSystems Raises USD2 Million in Financing 12
20/20 Gene Systems Raises USD1 Million in Financing Round 13
20/20 GeneSystems To Raise US$5 Million In Venture Financing 14
20/20 GeneSystems Secures USD0.15 Million in Venture Funding from Maryland Venture Fund 15
BHC Center of Financial & Investment Acquires Stake in 20/20 GeneSystems 16
20/20 GeneSystems Inc, Key Competitors 17
20/20 GeneSystems Inc, Key Employees 18
20/20 GeneSystems Inc, Subsidiaries 19

★海外企業調査レポート[2020 GeneSystems Inc-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Relief Therapeutics Holding AG (RLF):企業の財務・戦略的SWOT分析
    Summary Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. The company’s pipeline drug candidates include aviptadil for the treatment of sarcoidosis and low dose interleukin-6 t …
  • Outokumpu Oyj:企業の戦略・SWOT・財務情報
    Outokumpu Oyj - Strategy, SWOT and Corporate Finance Report Summary Outokumpu Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Abbott Point of Care Inc:企業の製品パイプライン分析2018
    Summary Abbott Point of Care Inc (Abbott Point), a subsidiary of Abbott Laboratories, is a medical device company that offers diagnostic products. The company manufactures, develops, and distributes medical diagnostic and data management products for in-vitro diagnostic and healthcare markets. Its p …
  • SilverSun Technologies Inc (SSNT):企業の財務・戦略的SWOT分析
    Summary SilverSun Technologies Inc (SilverSun) is a technology company that offers transformational business technology solutions and services for manufacturers and distributors. The company’s ERP software products comprise ERP X3, MAS90 and MAS200. It offers network services such as 24/7 remote net …
  • Schroders Plc
    Schroders Plc - Strategy, SWOT and Corporate Finance Report Summary Schroders Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Nishimatsu Construction Co., Ltd. (1820):企業の財務・戦略的SWOT分析
    Nishimatsu Construction Co., Ltd. (1820) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Duke Energy Corp (DUK):企業の財務・戦略的SWOT分析
    Duke Energy Corp (DUK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Nuvo Pharmaceuticals Inc (NRI):企業の財務・戦略的SWOT分析
    Summary Nuvo Pharmaceuticals Inc (Nuvo), formerly Nuvo Research Inc, is a healthcare company that offers portfolio of commercial products and pharmaceutical manufacturing capabilities. The company’s product portfolio includes pennsaid, heated lidocaine and tetracaine patches. Its products deliver dr …
  • Affimed GmbH (AFMD):企業の財務・戦略的SWOT分析
    Summary Affimed GmbH (Affimed), formerly Affimed Therapeutics AG, a subsidiary of Affimed NV, discovers and develops immunotherapies to treat hematologic cancers and solid tumors. The company is investigating AFM13, an innate cell engager, for the treatment of Peripheral T cell lymphoma, transformed …
  • Arkle Resources Plc:企業の戦略・SWOT・財務分析
    Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report Summary Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • The Independent Order of Foresters:企業の戦略的SWOT分析
    The Independent Order of Foresters - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Alzinova AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Alzinova AB (Alzinova) is a pharmaceutical company that discovers and develops therapeutics for the treatment of Alzheimer’s disease. The company develops amyloid beta CC peptide technology, which offers long-term research and development capabilities including the discovery and development …
  • TEGNA Inc (TGNA):企業の財務・戦略的SWOT分析
    TEGNA Inc (TGNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • ADNOC Distribution-石油・ガス分野:企業M&A・提携分析
    Summary ADNOC Distribution, a subsidiary of Abu Dhabi National Oil Company is an integrated energy company. The company carries out the marketing and distribution of petroleum products within the UAE and internationally. The markets and distributes lubes, fuel and gas. The company is also a distribu …
  • Vitabiotics Ltd:企業の戦略的SWOT分析
    Vitabiotics Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Therapure Biopharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Therapure Biopharma Inc (Therapure) is a biotherapeutics company that enhances patient care through its three divisions: therapure biomanufacturing, therapure innovations and evolve biologics. The company's therapure biomanufacturing division offers pipeline products such as TBI 301, TBI 302 …
  • First Quantum Minerals Ltd:企業のM&A・事業提携・投資動向
    First Quantum Minerals Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's First Quantum Minerals Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Biohaven Pharmaceutical Holding Company Ltd (BHVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that include …
  • MannKind Corp (MNKD):医療機器:M&Aディール及び事業提携情報
    Summary MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high …
  • Kratos Defense & Security Solutions, Inc.:企業の戦略・SWOT・財務情報
    Kratos Defense & Security Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kratos Defense & Security Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆